Sequence of early vascular events after photodynamic therapy

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 5, 2003, Pages 2147-2154

  Michels, Stephan ^a   Schmidt Erfurth, Ursula ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIODE LASER; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

CHOROID; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES;

EID: 0037408375     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0604     Document Type: Article

References (28)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Arch Ophthalmol. 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119:198-207.
3. Verteporfin in Photodynamic Therapy [VIP] Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology. 2001;108:841-852.
4. Verteporfin In Photodynamic Therapy [VIP] Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - VIP report 2. Am J Ophthalmol. 2001;131: 541-560.
5. Fingar V. Vascular effects of photodynamic therapy. J Clin Laser Med Surg. 1996;14:323-328.
6. Fingar V, Kik P, Haydon P, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer. 1999;79:1702-1708.
7. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
8. Fogelman AM, Berliner JA, Van Lenten BJ, et al. Lipoprotein receptors and endothelial cells. Semin Thromb Hemost. 1988;14:206-209.
9. Gaffney J, West D, Arnold F, et al. Differences in the uptake of modified low-density lipoproteins by tissue cultured endothelial cells. J Cell Sci. 1985;79:317-325.
10. Michels S, Barbazetto I, Schmidt-Erfurth U. Choroidal changes associated with photodynamic therapy: clinical course of two years in 38 patients. Klin Monatsbl Augenheilkd. 2000;216:1-6.
11. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularizations and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
12. Schmidt-Erfurth U, Schlötzer-Schrehardt U, Viestenz A, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844.
13. Rodgers M. On the problems involved in detecting luminescence from singlet oxygen in biological specimens. J Photochem Photobiol B. 1988;1:371-373.
14. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte T, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953-1961.
15. Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Bimgruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularisation. Laser Surg Med. 1995;17:178-188.
16. Lin SC, Lin CP, Feld JR, et al. The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res. 1994;13:513-522.
17. Schmidt-Erfurth U, Bauman W, Gragoudas E, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology. 1994;101:89-99.
18. Schmidt-Erfurth U, Hasan T, Flotte T. Photodynamic therapy of experimental, intraocular tumors with benzoporphyrin-lipoprotein. Ophthalmology. 1994;91:348-356.
19. Miller H, Miller B. Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol. 1993;111:855-860.
20. Miller J, Walsh A, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularisation using lipoprotein delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
21. Peyman GA, Kazi AA, Unal M, et al. Problems with and pitfalls of photodynamic therapy. Ophthalmology. 2000;107:29-35.
22. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatment in phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187.
23. Schmidt-Erfurth U. Indocyanine green angiography and retinal sensitivity after photodynamic therapy of subfoveal choroidal neovascularization. Semin Ophthalmol. 1999;14:35-44.
24. Battaglia Parodi M, Da Pozzo S, Ravalico G. Early angiographic changes after laser treatment of choroidal neovascularization in age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2001;239:900-908.
25. Lanzetta P, Michielotto P, Pirracchio A, Bandello F. Early vascular changes induced by transpupillary thermotherapy of choroidal neovascularization. Ophthalmology. 2002;109:1098-1104.
26. Flower RW. Expanded hypothesis on the mechanism of photodynamic therapy action on choroidal neovascularization. Retina. 1999;19:365-369.
27. Shiraga F, Shiragami C, Matsuo T, et al. Identification of ingrowth site of idiopathic subfoveal choroidal neovascularization by indocyanine green angiography. Ophthalmology. 2000;107:600-607.
28. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol. 1991;109:1242-1257.